Membrane Sealant Poloxamer P188 Protects Against Isoproterenol Induced Cardiomyopathy in Dystrophin Deficient Mice

BMC Cardiovascular Disorders

Volumn 11, Issue , 2011, Pages

  Spurney, Christopher F ^a,b   Guerron, Alfredo D ^a   Yu, Qing ^a   Sali, Arpana ^a   van der Meulen, Jack H ^a   Hoffman, Eric P ^a,b   Nagaraju, Kanneboyina ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Cardiomyopathy; Duchenne muscular dystrophy; Isoproterenol; Mdx; Poloxamer

Indexed keywords

COLLAGEN; DYE; DYSTROPHIN; EVANS BLUE; ISOPRENALINE; PICROSIRIUS DYE; POLOXAMER; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARDIOVASCULAR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOMYOPATHY; CONTROLLED STUDY; DRUG TARGETING; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART RATE; MEAN ARTERIAL PRESSURE; MOUSE; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; STAINING; SYSTOLE; SYSTOLIC BLOOD PRESSURE; ANALYSIS OF VARIANCE; ANIMAL; AORTA VALVE; BLOOD PRESSURE; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECT; FIBROSIS; GENETICS; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART STROKE VOLUME; HEART VENTRICLE PRESSURE; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SKELETAL MUSCLE; TIME; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ADRENERGIC BETA-AGONISTS; ANALYSIS OF VARIANCE; ANIMALS; AORTIC VALVE; BLOOD PRESSURE; BODY WEIGHT; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; COLLAGEN; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DYSTROPHIN; FEMALE; FIBROSIS; HEART RATE; INJECTIONS, INTRAPERITONEAL; ISOPROTERENOL; MICE; MICE, INBRED MDX; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIAL CONTRACTION; MYOCARDIUM; POLOXAMER; STROKE VOLUME; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 79955879424     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-11-20     Document Type: Article

References (27)

1. Gulati S, Saxena A, Kumar V, Kalra V. Duchenne muscular dystrophy: prevalence and patterns of cardiac involvement. Indian J Pediatr 2005, 72(5):389-393. 10.1007/BF02731732, 15973020.
2. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, Levin LS. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord 2004, 14(8-9):491-496. 10.1016/j.nmd.2004.04.007, 15336690.
3. Spurney CF, Knoblach S, Pistilli EE, Nagaraju K, Martin GR, Hoffman EP. Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul Disord 2008, 18(5):371-381. 10.1016/j.nmd.2008.03.008, 2430663, 18440230.
4. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, Van Der Meulen JH, Cha HJ, Pistilli EE, Partridge TA, Hoffman EP, Nagaraju K. Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 2009, 39(5):591-602. 10.1002/mus.21211, 19260102.
5. Kamogawa Y, Biro S, Maeda M, Setoguchi M, Hirakawa T, Yoshida H, Tei C. Dystrophin-deficient myocardium is vulnerable to pressure overload in vivo. Cardiovasc Res 2001, 50(3):509-515. 10.1016/S0008-6363(01)00205-X, 11376626.
6. Danialou G, Comtois AS, Dudley R, Karpati G, Vincent G, Des Rosiers C, Petrof BJ. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J 2001, 15(9):1655-1657.
7. Buyse GM, Van der Mieren G, Erb M, D'Hooge J, Herijgers P, Verbeken E, Jara A, Van Den Bergh A, Mertens L, Courdier-Fruh I, Barzaghi P, Meier T. Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur Heart J 2009, 30(1):116-124. 2639086, 18784063.
8. Van Erp C, Irwin NG, Hoey AJ. Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve 2006, 34(3):327-334. 10.1002/mus.20590, 16770778.
9. Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005, 436(7053):1025-1029. 10.1038/nature03844, 16025101.
10. Yue Y, Skimming JW, Liu M, Strawn T, Duan D. Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice. Hum Mol Genet 2004, 13(15):1669-1675. 10.1093/hmg/ddh174, 2431460, 15190010.
11. Ballas SK, Files B, Luchtman-Jones L, Benjamin L, Swerdlow P, Hilliard L, Coates T, Abboud M, Wojtowicz-Praga S, Grindel JM. Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome. Hemoglobin 2004, 28(2):85-102. 10.1081/HEM-120035919, 15182051.
12. Lee RC, River LP, Pan FS, Ji L, Wollmann RL. Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo. Proc Natl Acad Sci USA 1992, 89(10):4524-4528. 10.1073/pnas.89.10.4524, 49115, 1584787.
13. Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, Gordish-Dressman H, Rayavarapu S, van der Meulen J, Hoffman EP, Nagaraju K. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 2011, 16(1):87-95. 10.1177/1074248410381757, 21304057.
14. Brooks SV, Faulkner JA. Contractile properties of skeletal muscles from young, adult and aged mice. J Physiol 1988, 404:71-82. 1190815, 3253447.
15. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004, 24(19):8467-8476. 10.1128/MCB.24.19.8467-8476.2004, 516756, 15367668.
16. Frey N, Barrientos T, Shelton JM, Frank D, Rutten H, Gehring D, Kuhn C, Lutz M, Rothermel B, Bassel-Duby R, Richardson JA, Katus HA, Hill JA, Olson EN. Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress. Nat Med 2004, 10(12):1336-1343. 10.1038/nm1132, 15543153.
17. Keys JR, Greene EA, Cooper CJ, Naga Prasad SV, Rockman HA, Koch WJ. Cardiac hypertrophy and altered beta-adrenergic signaling in transgenic mice that express the amino terminus of beta-ARK1. Am J Physiol Heart Circ Physiol 2003, 285(5):H2201-2211.
18. Zahabi A, Picard S, Fortin N, Reudelhuber TL, Deschepper CF. Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. J Biol Chem 2003, 278(48):47694-47699. 10.1074/jbc.M309661200, 14500707.
19. Emanuele RM. FLOCOR: a new anti-adhesive, rheologic agent. Expert Opin Investig Drugs 1998, 7(7):1193-1200. 10.1517/13543784.7.7.1193, 15992024.
20. Gibbs WJ, Hagemann TM. Purified poloxamer 188 for sickle cell vaso-occlusive crisis. Ann Pharmacother 2004, 38(2):320-324.
21. Townsend D, Turner I, Yasuda S, Martindale J, Davis J, Shillingford M, Kornegay JN, Metzger JM. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 2010, 120(4):1140-1150. 10.1172/JCI41329, 2846060, 20234088.
22. Quinlan JG, Wong BL, Niemeier RT, McCullough AS, Levin L, Emanuele M. Poloxamer 188 failed to prevent exercise-induced membrane breakdown in mdx skeletal muscle fibers. Neuromuscul Disord 2006, 16(12):855-864. 10.1016/j.nmd.2006.09.016, 17118658.
23. Townsend D, Yasuda S, Metzger J. Cardiomyopathy of Duchenne muscular dystrophy: pathogenesis and prospect of membrane sealants as a new therapeutic approach. Expert Rev Cardiovasc Ther 2007, 5(1):99-109. 10.1586/14779072.5.1.99, 17187461.
24. Loufrani L, Levy BI, Henrion D. Defect in microvascular adaptation to chronic changes in blood flow in mice lacking the gene encoding for dystrophin. Circ Res 2002, 91(12):1183-1189. 10.1161/01.RES.0000047505.11002.81, 12480820.
25. Loufrani L, Matrougui K, Gorny D, Duriez M, Blanc I, Levy BI, Henrion D. Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin. Circulation 2001, 103(6):864-870. 2233878, 11171796.
26. Ng R, Metzger JM, Claflin DR, Faulkner JA. Poloxamer 188 reduces the contraction-induced force decline in lumbrical muscles from mdx mice. Am J Physiol Cell Physiol 2008, 295(1):C146-150. 10.1152/ajpcell.00017.2008, 2493563, 18495816.
27. Townsend D, Yasuda S, Li S, Chamberlain JS, Metzger JM. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther 2008, 16(5):832-835. 10.1038/mt.2008.52, 2592846, 18414480.